La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

BIONET Gestione

Gestione criteri di controllo 1/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	18.2yrs

Aggiornamenti recenti sulla gestione

Recent updates

Should You Investigate BIONET Corp. (GTSM:1784) At NT$43.50?

Apr 10

If You Had Bought BIONET (GTSM:1784) Shares Three Years Ago You'd Have Earned 46% Returns

Feb 10

AMMINISTRATORE DELEGATO

BIONET non ha un CEO, o non abbiamo dati su di loro.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Shao-Hua Huang	Independent Director	17.8yrs	Nessun dato	0.026% NT$ 1.4m
John Wagner	Member of Advisory Board	no data	Nessun dato	Nessun dato
Wen Yan	Independent Director	18.2yrs	Nessun dato	Nessun dato
Zheng Huang	Director	19.6yrs	Nessun dato	Nessun dato
Cheng-Hsian Coi	Director	16.8yrs	Nessun dato	3.83% NT$ 211.8m
Wen Zhang	Director	21.3yrs	Nessun dato	1.97% NT$ 108.8m
Cui Zhang	Supervisor	24yrs	Nessun dato	Nessun dato
Zhao Fen Zhang	Supervisor	16.8yrs	Nessun dato	Nessun dato
Han Zhang	Director	18.2yrs	Nessun dato	Nessun dato
Shi Liang	Director	10.4yrs	Nessun dato	0.51% NT$ 28.1m
Cheng-Hsien Tsai	Chairman of the Board	no data	Nessun dato	Nessun dato
Han Tung Chang	Director	no data	Nessun dato	Nessun dato

18.2yrs

Durata media

57yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 1784 è composto da personale esperto e esperto (durata media dell'incarico 18.2 anni).

BIONET Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

BIONET Corp., Annual General Meeting, Jun 19, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Second quarter 2024 earnings released: EPS: NT$0.35 (vs NT$0.67 in 2Q 2023)

Investor sentiment deteriorates as stock falls 17%

Now 23% undervalued

Investor sentiment improves as stock rises 15%

New minor risk - Share price stability

Investor sentiment improves as stock rises 15%

First quarter 2024 earnings released: EPS: NT$0.47 (vs NT$0.49 in 1Q 2023)

Investor sentiment improves as stock rises 18%

BIONET Corp., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: EPS: NT$1.67 (vs NT$0.80 in FY 2022)

Third quarter 2023 earnings released: EPS: NT$0.40 (vs NT$0.34 in 3Q 2022)

Upcoming dividend of NT$0.70 per share at 1.0% yield

Second quarter 2023 earnings released: EPS: NT$0.67 (vs NT$0.15 in 2Q 2022)

New major risk - Share price stability

Less than half of directors are independent

Upcoming dividend of NT$0.49 per share

Second quarter 2022 earnings released: EPS: NT$0.15 (vs NT$0.25 in 2Q 2021)

First quarter 2022 earnings released: EPS: NT$0.10 (vs NT$0.25 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: NT$0.56 (vs NT$0.27 in FY 2020)

Third quarter 2021 earnings released: EPS NT$0.11 (vs NT$0.033 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.25 (vs NT$0.003 loss in 2Q 2020)

Upcoming dividend of NT$0.18 per share

First quarter 2021 earnings released: EPS NT$0.25 (vs NT$0.11 in 1Q 2020)

Should You Investigate BIONET Corp. (GTSM:1784) At NT$43.50?

Full year 2020 earnings released: EPS NT$0.27 (vs NT$0.14 in FY 2019)

If You Had Bought BIONET (GTSM:1784) Shares Three Years Ago You'd Have Earned 46% Returns

New 90-day low: NT$35.85

New 90-day high: NT$42.95

Third quarter 2020 earnings released: EPS NT$0.03

New 90-day low: NT$38.35

First half earnings released

AMMINISTRATORE DELEGATO

Membri del Consiglio di amministrazione

Durata media

Età media